Matthew F Griffith1,2,3, Laura C Feemster4,5, Steven B Zeliadt4, Lucas M Donovan4,5, Laura J Spece4,5, Edmunds M Udris4, David H Au4,5. 1. Seattle-Denver Center of Innovation for Veteran-Centered & Value-Driven Care, VA Eastern Colorado Health Care System, Aurora, CO, USA. Matthew.griffith@va.gov. 2. Seattle-Denver Center of Innovation for Veteran-Centered & Value-Driven Care, VA Puget Sound Health Care System, Seattle, WA, USA. Matthew.griffith@va.gov. 3. Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington, Seattle, WA, USA. Matthew.griffith@va.gov. 4. Seattle-Denver Center of Innovation for Veteran-Centered & Value-Driven Care, VA Puget Sound Health Care System, Seattle, WA, USA. 5. Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington, Seattle, WA, USA.
Abstract
BACKGROUND: Inhaled corticosteroid (ICS) use among patients with COPD increases the risk of pneumonia and other complications. Current recommendations limit ICS use to patients with frequent or severe COPD exacerbations. However, use of ICS among patients with COPD is common and may be occurring both among those with mild disease (overuse) and those misdiagnosed with COPD (misuse). OBJECTIVE: To identify patients without identifiable indication for ICS and assess patient and provider characteristics associated with potentially inappropriate to targeted in de-implementation efforts DESIGN: We performed a cross-sectional study of patients with COPD in the Veterans Affairs (VA) system with recent spirometry. PARTICIPANTS: After setting an index date, we identified individuals with a clinical diagnosis of COPD who had spirometry completed in the prior 5 years. We excluded individuals with an appropriate indication for ICS based on the 2017 GOLD statement, including asthma and a recent history of frequent or severe exacerbations. MAIN MEASURES: ICS use without identifiable indication KEY RESULTS: We identified 26,536 patients with COPD without an identifiable indication for ICS. Nearly ¼ of patients (n = 6330) filled ≥2 prescriptions for ICS in the year prior to the index date. We found that older age (adjusted prevalence ratio [APR] 1.06 per decade, 95% confidence interval [CI] 1.04-1.08), white race (APR 1.11, 95% CI 1.05-1.19), and more primary care visits (APR 1.05 per visit, 95% CI 1.03-1.07) were associated with increased likelihood of potentially inappropriate use. Primary care clinic complexity and provider training were not associated with ICS use. Among patients misdiagnosed with COPD, we found that 14% used ICS. CONCLUSIONS: Potentially inappropriate ICS use is common among patients with and without airflow obstruction who are diagnosed with COPD. We identified patient comorbidities and patterns of healthcare utilization that increase the likelihood of ICS use that could be targeted for system-level de-implementation interventions.
BACKGROUND: Inhaled corticosteroid (ICS) use among patients with COPD increases the risk of pneumonia and other complications. Current recommendations limit ICS use to patients with frequent or severe COPD exacerbations. However, use of ICS among patients with COPD is common and may be occurring both among those with mild disease (overuse) and those misdiagnosed with COPD (misuse). OBJECTIVE: To identify patients without identifiable indication for ICS and assess patient and provider characteristics associated with potentially inappropriate to targeted in de-implementation efforts DESIGN: We performed a cross-sectional study of patients with COPD in the Veterans Affairs (VA) system with recent spirometry. PARTICIPANTS: After setting an index date, we identified individuals with a clinical diagnosis of COPD who had spirometry completed in the prior 5 years. We excluded individuals with an appropriate indication for ICS based on the 2017 GOLD statement, including asthma and a recent history of frequent or severe exacerbations. MAIN MEASURES: ICS use without identifiable indication KEY RESULTS: We identified 26,536 patients with COPD without an identifiable indication for ICS. Nearly ¼ of patients (n = 6330) filled ≥2 prescriptions for ICS in the year prior to the index date. We found that older age (adjusted prevalence ratio [APR] 1.06 per decade, 95% confidence interval [CI] 1.04-1.08), white race (APR 1.11, 95% CI 1.05-1.19), and more primary care visits (APR 1.05 per visit, 95% CI 1.03-1.07) were associated with increased likelihood of potentially inappropriate use. Primary care clinic complexity and provider training were not associated with ICS use. Among patients misdiagnosed with COPD, we found that 14% used ICS. CONCLUSIONS: Potentially inappropriate ICS use is common among patients with and without airflow obstruction who are diagnosed with COPD. We identified patient comorbidities and patterns of healthcare utilization that increase the likelihood of ICS use that could be targeted for system-level de-implementation interventions.
Entities:
Keywords:
COPD care quality; de-implementation; de-prescribing; misuse; overuse
Authors: Kenneth R Chapman; Stephen I Rennard; Angeli Dogra; Roger Owen; Cheryl Lassen; Benjamin Kramer Journal: Chest Date: 2011-02-24 Impact factor: 9.410
Authors: Dennis E Niewoehner; Kathryn Rice; Claudia Cote; Daniel Paulson; J Allen D Cooper; Larry Korducki; Cara Cassino; Steven Kesten Journal: Ann Intern Med Date: 2005-09-06 Impact factor: 25.391
Authors: R Casaburi; D A Mahler; P W Jones; A Wanner; Pedro G San; R L ZuWallack; S S Menjoge; C W Serby; T Witek Journal: Eur Respir J Date: 2002-02 Impact factor: 16.671
Authors: Peter M A Calverley; Julie A Anderson; Bartolome Celli; Gary T Ferguson; Christine Jenkins; Paul W Jones; Julie C Yates; Jørgen Vestbo Journal: N Engl J Med Date: 2007-02-22 Impact factor: 91.245
Authors: W Vincken; J A van Noord; A P M Greefhorst; Th A Bantje; S Kesten; L Korducki; P J G Cornelissen Journal: Eur Respir J Date: 2002-02 Impact factor: 16.671
Authors: Jadwiga A Wedzicha; Peter M A Calverley; Terence A Seemungal; Gerry Hagan; Zainab Ansari; Robert A Stockley Journal: Am J Respir Crit Care Med Date: 2007-10-04 Impact factor: 21.405
Authors: Andrea Koch; Emilio Pizzichini; Alan Hamilton; Lorna Hart; Lawrence Korducki; Maria Cristina De Salvo; Pierluigi Paggiaro Journal: Int J Chron Obstruct Pulmon Dis Date: 2014-07-05
Authors: Matthew F Griffith; Hung-Yuan P Chen; David B Bekelman; Laura C Feemster; Laura J Spece; Lucas M Donovan; David H Au; Evan P Carey Journal: Ann Am Thorac Soc Date: 2021-03
Authors: Jennifer K Quint; Jukka Montonen; Daina B Esposito; Xintong He; Leslie Koerner; Laura Wallace; Alberto de la Hoz; Marc Miravitlles Journal: Adv Ther Date: 2021-03-15 Impact factor: 3.845